Generated Narrative: Citation 179637

url: Citation 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179637, https://pubmed.ncbi.nlm.nih.gov/18508207, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.3

version: 1.0.0-ballot2

title: 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

status: Active

date: 2025-03-28 17:11:38+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2008-12-16

lastReviewDate: 2021-10-20

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2007-11-22

statusDate

activity: PubMed Pubstatus of Revised

period: ?? --> 2008-04-08

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2008-04-09

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2008-05-30 09:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2008-12-17 09:00:00+0000

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2008-05-30 09:00:00+0000

statusDate

activity: PubMed Pubstatus of PMC release

period: ?? --> 2009-09-01

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/18508207, mid/NIHMS61453, https://www.ncbi.nlm.nih.gov/pmc//PMC2613766, https://doi.org/10.1016/j.drugalcdep.2008.04.002, pii/S0376-8716(08)00140-3

Titles

-	Type	Language	Text
*	Primary title	English	A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Abstracts

-	Type	Text
*	Primary human use	CONTEXT: Lofexidine is an alpha-2-adrenergic receptor agonist that is approved in the United Kingdom for the treatment of opioid withdrawal symptoms. Lofexidine has been reported to have more significant effects on decreasing opioid withdrawal symptoms with less hypotension than clonidine. OBJECTIVE: To demonstrate that lofexidine is well tolerated and effective in the alleviation of observationally defined opioid withdrawal symptoms in opioid dependent individuals undergoing medically supervised opioid detoxification as compared to placebo. DESIGN: An inpatient, Phase 3, placebo-controlled, double-blind, randomized multi-site trial with three phases: (1) opioid agonist stabilization phase (days 1-3), (2) detoxification/medication or placebo phase (days 4-8), and (3) post detoxification/medication phase (days 9-11). SUBJECTS: Sixty-eight opioid dependent subjects were enrolled at three sites with 35 randomized to lofexidine and 33 to placebo. MAIN OUTCOME MEASURE: Modified Himmelsbach Opiate Withdrawal Scale (MHOWS) on study day 5 (second opioid detoxification treatment day). RESULTS: Due to significant findings, the study was terminated early. On the study day 5 MHOWS, subjects treated with lofexidine had significantly lower scores (equating to fewer/less severe withdrawal symptoms) than placebo subjects (least squares means 19.5+/-2.1 versus 30.9+/-2.7; p=0.0019). Lofexidine subjects had significantly better retention in treatment than placebo subjects (38.2% versus 15.2%; Log rank test p=0.01). CONCLUSIONS: Lofexidine is well tolerated and more efficacious than placebo for reducing opioid withdrawal symptoms in inpatients undergoing medically supervised opioid detoxification.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/6282816/

type: cites

classifier: Journal Article

citation:

Aghajanian GK. Central noradrenergic neurons: a locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. J Clin Psychiatry. 1982;43(6 Pt 2):20–24.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/216919/

type: cites

classifier: Journal Article

citation:

Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature. 1978;276(5684):186–188.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/6890373/

type: cites

classifier: Journal Article

citation:

Aigner A, Schmidt U. Lofexidine, a new, antihypertensive imidazoline derivative. Clinical profile of action with single-drug treatment and in combination with hydrochlorothiazide. Arzneimittelforschung. 1982;32(8a):976–983.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/10085500/

type: cites

classifier: Journal Article

citation:

Akhurst JS. The use of lofexidine by drug dependency units in the United Kingdom. Eur Addict Res. 1999;5(1):43–49.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/2903226/

type: cites

classifier: Journal Article

citation:

Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 1998;8(11):4287–4298.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/9313908/

type: cites

classifier: Journal Article

citation:

Aston-Jones G, Hirata H, Akaoka H. Local opiate withdrawal in locus coeruleus in vivo. Brain Res. 1997;765(2):331–336.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/8957147/

type: cites

classifier: Journal Article

citation:

Bearn J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1996;43(1–2):87–91.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/9649976/

type: cites

classifier: Journal Article

citation:

Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend. 1998;50:227–232.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/4058799/

type: cites

classifier: Journal Article

citation:

Buccafusco JJ, Marshall DC. Dorsal root lesions block the expression of morphine withdrawal elicited from the rat spinal cord. Neurosci Lett. 1985;59(3):319–324.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/9649979/

type: cites

classifier: Journal Article

citation:

Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50(3):251–254.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/2997411/

type: cites

classifier: Journal Article

citation:

Freedman JE, Aghajanian GK. Opiate and alpha 2-adrenoceptor responses of rat amygdaloid neurons: co-localization and interactions during withdrawal. J Neurosci. 1985;5(11):3016–3024.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/7338185/

type: cites

classifier: Journal Article

citation:

Gold MS, Pottash AC, Sweeney DR, Extein I, Annitto WJ. Opiate detoxification with lofexidine. Drug Alcohol Depend. 1981;8(4):307–315.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/15102558/

type: cites

classifier: Journal Article

citation:

Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004;5(4):713–725.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/3048954/

type: cites

classifier: Journal Article

citation:

Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 1988;21(3):253–259.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/2248123/

type: cites

classifier: Journal Article

citation:

Gossop M. The development of a short opiate withdrawal scale. Addict Behav. 1990;15(5):487–490.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/11895270/

type: cites

classifier: Journal Article

citation:

Gowing LR, Farrell M, Ali RL, White JM. Alpha 2-adrenergic agonists in opioid withdrawal. Addiction. 2002;97(1):49–58.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/15495025/

type: cites

classifier: Journal Article

citation:

Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews CD002024. 2004

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/3687892/

type: cites

classifier: Journal Article

citation:

Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293–308.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/8747752/

type: cites

classifier: Journal Article

citation:

Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: medication development issues for opiate addiction. Neuropsychopharmacology. 1995;13:269–294.

relatesTo

type: cites

citation:

Herman BH, O'Brien CP. Clinical medications development for opiate addiction: Focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Seminars in Neuroscience. 1997;9:158–172.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/12095666/

type: cites

classifier: Journal Article

citation:

Howells C, Allen S, Gupta J, Stillwell G, Marsden J, Farrell M. Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug Alcohol Depend. 2002;67(2):169–176.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/11343531/

type: cites

classifier: Journal Article

citation:

Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503–508.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/3954551/

type: cites

classifier: Journal Article

citation:

Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–294.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/6129948/

type: cites

classifier: Journal Article

citation:

Jarrott B, Louis WJ, Summers RJ. Characterization of central alpha-adrenoceptors using 3H-clonidine and its derivatives. Chest. 1983;83 Suppl 2:S339–S340.

relatesTo

type: cites

citation:

Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs (methods used in man) In: Martin WR, editor. Handbook of Experimental Pharmacology. Vol 45. Berlin: Springer-Verlag; 1977. pp. 197–258.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/9031821/

type: cites

classifier: Journal Article

citation:

Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44(1):57–61.

relatesTo

type: cites

citation:

Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc.; 1980.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/3977557/

type: cites

classifier: Journal Article

citation:

Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry. 1985;42(4):391–394.

relatesTo

type: cites

citation:

Kolb MR, Himmelsbach CK. Clinical studies of drug addiction. III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Amer. J. Psychiatry. 1938;94:759–797.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/9363412/

type: cites

classifier: Journal Article

citation:

Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48(2):127–133.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/7901041/

type: cites

classifier: Journal Article

citation:

Marjamaki A, Luomala K, Ala-Uotila S, Scheinen M. Use of recombinant human alpha 2-adrenoceptors to characterize subtype selectively of antagonist binding. Eur J Pharmacol. 1993;246(3):219–226.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/24288193/

type: cites

classifier: Journal Article

citation:

National Survey on Drug Use and Health. 2006. [accessed on April 10, 2008]. Availabel at: http://www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.cfm.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/497341/

type: cites

classifier: Journal Article

citation:

O’Brien PC, Fleming TR. A multiple testing procedure for clinical trails. Biometrics. 1979;35(3):549–556.

relatesTo

type: cites

citation:

Office of National Drug Control Policy. Heroin Fact Sheet. 2003. [Accessed February 6, 2006]. Available at: http://www.whitehousedrugpolicy.gov/publications/factsht/heroin/index.html.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/2867050/

type: cites

classifier: Journal Article

citation:

Preston KL, Bigelow GE. Pharmacological advances in addiction treatment. Int J Addict. 1985;20(6–7):845–867.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/16367987/

type: cites

classifier: Journal Article

citation:

Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J. A comparison of buprenorphine annd lofexidine for community opiate detoxification: results from a randomized controlled trail. Addict. 2005;100(12):1860–1867.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/7190295/

type: cites

classifier: Journal Article

citation:

Shearman GT, Lal H, Ursillo RC. Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol Biochem Behav. 1980;12(4):573–575.

relatesTo

type: cites

citation:

Snedecor GW, Cochran WG. Statistical Methods. Ames, IA: Iowa State University Press; 1967.

relatesTo

type: cites

citation:

Substance Abuse and Mental Health Data Archive. National Household Survey on Drug Abuse (NHSDA) series. 2003. [Accessed February 6, 2006]. Available at http://www.icpsr.umich.edu/SAMHDA/ and http://webapp.icpsr.umich.edu/cocoon/SAMHDA-SERIES/00064.xml.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/1665747/

type: cites

classifier: Journal Article

citation:

Uhlen S, Wikberg JE. Delineation of three pharmacological subtypes of alpha 2-adrenoceptor in the rat kidney. Br J Pharmacol. 1991;104(3):657–6419.

relatesTo

type: cites

citation:

Vocci FJ. Opiates and addiction. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors. Handbook of Contemporary Neuropharmacology Volume 2. John Wiley and Sons publisher; 2007. pp. 691–705.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/6811916/

type: cites

classifier: Journal Article

citation:

Washton AM, Resnick RB, Perzel JF, Garwood J. Opiate detoxification using lofexidine. NIDA Res Monogr. 1982;41:261–263.

relatesTo

TargetUri: https://pubmed.ncbi.nlm.nih.gov/11714592/

type: cites

classifier: Journal Article

citation:

White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. Drug Alcohol Depend. 2001;65(1):77–83.

relatesTo

type: cites

citation:

Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Chiang CN, Fisher C, Kampman K, Dhopesh V, Cornish J, Walsh B, Davies K, Vocci F, Bridge P, Ling W, O’Brien CP. NIDA Research Monograph. Rockville: DHHS/NIH/NIDA; 1999. In-patient safety evaluation of lofexidine (alpha-2 adrenergic agonist) for opiate withdrawal; p. 227.

relatesTo

type: cites

citation:

Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Chiang CN, Fisher C, Kampman K, Dhopesh V, Cornish J, Walsh B, Davies K, Vocci F, Bridge P, Ling W, O’Brien CP. In-patient safety evaluation of lofexidine (alpha-2 adrenergic agonist) for opiate detoxification. Drug Alcohol Depend. 2001;63:S175.

publicationForm

publishedIn

type: Periodical

identifier: Print ISSN Type/0376-8716, ISOAbbreviation/Drug Alcohol Depend, ISSN Linking/0376-8716, Medline Title Abbreviation/Drug Alcohol Depend, NLM Unique ID/7513587

title: Drug and alcohol dependence

publisherLocation: Ireland

citedMedium: Print

volume: 97

issue: 1-2

articleDate: 2008-09-01

publicationDateText: 2008-Sep-01

pageString: 158-68

publicationForm

citedMedium: Internet without issue

articleDate: 2008-05-27

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/18508207/

webLocation

classifier: DOI Based

url: https://doi.org/10.1016/j.drugalcdep.2008.04.002

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Chemical

classifier: Adrenergic alpha-Agonists, Analgesics, Opioid, Clonidine, lofexidine

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Yu E

forenameInitials: E

affiliation: University of Pennsylvania & Philadelphia Veterans Affairs Medical Center, Philadelphia VAMC 116, University & Woodland Avenues, Philadelphia, PA 19104, USA. yu_e@mail.trc.upenn.edu <yu_e@mail.trc.upenn.edu>

entry

contributor: Miotto K

forenameInitials: K

entry

contributor: Akerele E

forenameInitials: E

entry

contributor: Montgomery A

forenameInitials: A

entry

contributor: Elkashef A

forenameInitials: A

entry

contributor: Walsh R

forenameInitials: R

entry

contributor: Montoya I

forenameInitials: I

entry

contributor: Fischman MW

forenameInitials: MW

entry

contributor: Collins J

forenameInitials: J

entry

contributor: McSherry F

forenameInitials: F

entry

contributor: Boardman K

forenameInitials: K

entry

contributor: Davies DK

forenameInitials: DK

entry

contributor: O'Brien CP

forenameInitials: CP

entry

contributor: Ling W

forenameInitials: W

entry

contributor: Kleber H

forenameInitials: H

entry

contributor: Herman BH

forenameInitials: BH

Generated Narrative: Practitioner #contributor0

name: Elmer Yu

Generated Narrative: Practitioner #contributor1

name: Karen Miotto

Generated Narrative: Practitioner #contributor2

name: Evaristo Akerele

Generated Narrative: Practitioner #contributor3

name: Ann Montgomery

Generated Narrative: Practitioner #contributor4

name: Ahmed Elkashef

Generated Narrative: Practitioner #contributor5

name: Robert Walsh

Generated Narrative: Practitioner #contributor6

name: Ivan Montoya

Generated Narrative: Practitioner #contributor7

name: Marian W Fischman

Generated Narrative: Practitioner #contributor8

name: Joseph Collins

Generated Narrative: Practitioner #contributor9

name: Frances McSherry

Generated Narrative: Practitioner #contributor10

name: Kathy Boardman

Generated Narrative: Practitioner #contributor11

name: David K Davies

Generated Narrative: Practitioner #contributor12

name: Charles P O'Brien

Generated Narrative: Practitioner #contributor13

name: Walter Ling

Generated Narrative: Practitioner #contributor14

name: Herbert Kleber

Generated Narrative: Practitioner #contributor15

name: Barbara H Herman

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

content

type: components (if present) include qualifier codings

classifier: Adrenergic alpha-Agonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

type: components (if present) include qualifier codings

classifier: Adult

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Analgesics, Opioid

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic

content

type: components (if present) include qualifier codings

classifier: Clonidine

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: analogs & derivatives

Components

-	Type	Classifier
*	is Major topic	Yes

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Data Collection

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Double-Blind Method

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Female

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Psychiatric Status Rating Scales

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Substance Abuse Detection

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Substance Withdrawal Syndrome

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

content

type: components (if present) include qualifier codings

classifier: Survival Analysis

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Treatment Outcome

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic